Business Wire

 Panasonic and KOSÉ Set to Commence Verification Test for Personalized Proposals Utilizing Snow Beauty Mirror

Share

Panasonic Corporation is collaborating with KOSÉ Corporation to conduct a joint verification test using Snow Beauty Mirror, a system under development by Panasonic, with the aim of offering personalized proposals at Maison KOSÉ, a store which is due to open on December 17. Through this initiative, Panasonic will help make new personalized proposals that meet the diverse needs of its customers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191205005971/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Snow Beauty Mirror (Displays the results of skin analysis covering five categories) (Photo: Business Wire)

People’s values and lifestyles are becoming increasingly diverse. In today’s world, everyone requires something different from their cosmetics. Meanwhile, customers are confronted with a deluge of information through the Internet and social media, which sometimes makes it difficult for them to select cosmetics that really suit their needs. A solution to this conundrum is personalized proposals which utilize digital technologies and data to introduce individuals to the optimal products and services.

Maison KOSÉ is a new type of concept store, a place where people will be able to come and experience these personalized proposals firsthand using Snow Beauty Mirror. Visitors will also be able to try out Customized Sheets (provisional name), which adopts the Make-up Sheet technology currently under development at Panasonic.

Functions of Snow Beauty Mirror and content of verification test

1. Skin analysis

All customers need to do is sit in front of the mirror. The system then analyzes the customer’s skin profile and displays numerical data instantly on the mirror. Contactless sensors embedded in the mirror detect the condition of both the skin’s surface and below the surface. With a degree of precision on par with medical devices, the system detects not only spots, wrinkles, smile lines, pores and skin tone, but also hidden spots otherwise invisible to the naked eye. Then, based on digital counselling and analysis results, the system recommends the optimal package for each individual customer from among KOSÉ’s products and services spanning multiple brands*1. This function utilizes facial recognition and image processing technologies used in digital cameras, et al.

2. Ideal face image system

Combining genetic algorithms, developed as a joint venture between KOSÉ and Meiji University, with Panasonic’s image processing technologies has enabled the creation of a system which makes it possible to visualize a person’s “ideal face” from facial image data—that is, how the customer would really like to appear. Snow Beauty Mirror’s high-precision skin analysis function detects the customer’s skin conditions in terms of pores, spots and wrinkles, as well as the skin’s tones and brightness, and adjusts the parameters of this data to create around 500,000 facial image patterns. The customer selects their preferred facial image from among randomly displayed facial images, generating their ideal face in a short time. The system can visualize the differences between the customer’s ideal face and current appearance, while providing tips on the perfect foundation tone, texture and application techniques to help them get closer to their ideal face.

3. Customized Sheets which apply Make-up Sheet technology

Currently under development at Panasonic, Make-up Sheets are ultra-thin*2 cosmetic sheets printed with tones that perfectly match the customer’s skin. They combine skin analysis data from Snow Beauty Mirror, and the company’s proprietary printing technology. Customers simply need to stick the sheets over areas of concern on their cheeks or temples.

In this verification test, Panasonic will combine its Make-up Sheet technology, proprietary skin tone analysis technology, and printing technology with KOSÉ’s extensive knowledge of cosmetic development. The aim is to create Customized Sheets (provisional name) that achieve a natural color match and an ideal fit with the customer’s skin.


Panasonic will continue to fuse its cutting-edge technologies with KOSÉ’s development capabilities in cosmetics to expand the scope of Snow Beauty Mirror, pursuing possibilities that go beyond the field of beauty treatment. In this way, the company will meet the diverse needs of its customers and better contribute to society through improved QOL.

Notes:
*1. KOSÉ Group’s skin care brands, excluding ALBION
*2. Thickness of 100 nanometers (one nanometer = one billionth of a meter)

About Maison KOSÉ

A fun concept store stocking and linking all KOSÉ brands*3, providing customers with an early chance to try a range of new software and hardware relating to cosmetics and beauty treatment. The store facilitates new forms of communication which fuse digital and experiential approaches, exploring new possibilities for the next generation of cosmetic experiences and working to connect customers digitally to the store. It also serves as a place of communication with customers, functioning as a seat of learning where information and experiences can be quickly fed back into the company.

*3 Excluding some products

About Panasonic

Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 582 subsidiaries and 87 associated companies worldwide, recording consolidated net sales of 8.003 trillion yen for the year ended March 31, 2019. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: https://www.panasonic.com/global.

Source: https://news.panasonic.com/global/press/data/2019/12/en191206-2/en191206-2.html

Related Links

[Video] Make-up Sheet / Technology & Innovation of Panasonic
https://channel.panasonic.com/contents/25818/

[Video] Solving skin concerns with innovation using the “Make-up Sheet” [Panasonic]
https://channel.panasonic.com/contents/25819/

Brand Story | Panasonic
https://www.panasonic.com/global/corporate/brand/story.html

Panasonic R&D Overview | Panasonic
https://www.panasonic.com/global/corporate/technology-design/r-and-d.html

Breakthrough Technology | Panasonic
https://www.panasonic.com/global/corporate/technology-design/technology.html

KOSÉ Corporation
https://www.kose.co.jp/global/en/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Panasonic
Innovation Strategy Office
Technology Public Relations Section
crdpress@ml.jp.panasonic.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye